Opiant Pharmaceuticals (Opiant Pharmaceuticals) Days Sales Outstanding : 0.00 (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals Days Sales Outstanding?

Opiant Pharmaceuticals's average Accounts Receivable for the three months ended in Sep. 2022 was $1.19 Mil. Opiant Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

The historical rank and industry rank for Opiant Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

OPNT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.51 Med: 77.77 Max: 147.97
Current: 147.97

During the past 13 years, Opiant Pharmaceuticals's highest Days Sales Outstanding was 147.97. The lowest was 11.51. And the median was 77.77.

OPNT's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 72.245 vs OPNT: 147.97

Opiant Pharmaceuticals's Days Sales Outstanding declined from Sep. 2021 (81.73) to Sep. 2022 (0.00).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Opiant Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Opiant Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Days Sales Outstanding Chart

Opiant Pharmaceuticals Annual Data

Trend

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Dec18

Dec19

Dec20

Dec21

Days Sales Outstanding

Get a 7-Day Free Trial

40.19

111.27

55.88

107.42

99.65

Opiant Pharmaceuticals Quarterly Data
	Oct17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Sales Outstanding	Get a 7-Day Free Trial															81.73	100.63	369.91	133.17	-

Competitive Comparison of Opiant Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Opiant Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opiant Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Days Sales Outstanding falls into.

Opiant Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Opiant Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

	Days Sales Outstanding (A: Dec. 2021 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )	*	Days in Period
=	( (8.911	+	13.327)	/	2 )	/	40.725	*	365
=	11.119					/	40.725	*	365
=	99.65

Opiant Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding (Q: Sep. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Sep. 2022 ))	/	count )	/	Revenue (A: Sep. 2022 )	*	Days in Period
=	( (2.336	+	0.041)	/	2 )	/	0	*	365 / 4
=	1.1885					/	0	*	365 / 4
=	N/A

Opiant Pharmaceuticals (NAS:OPNT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Opiant Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401

Website

https://www.opiant.com

Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Executives

David D O'toole	officer: Chief Financial Officer	1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath	other: UK Managing Director	C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal	director, 10 percent owner, officer: Chief Executive Officer	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick	officer: Chief Scientific Officer	C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman	other: General Counsel	233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth	officer: Chief Commercial Officer	233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair	director, 10 percent owner, officer: Executive Chairman	86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson	other: General Counsel	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134